Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Viatris shares recorded ... ($11.9B) in revenue for Q1, implying ~19% YoY growth but signaling a ~9% decline compared to the preceding quarter as Wegovy sales plunged ~13% QoQ to DKK 17.4B ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Novo Nordisk (NVO) said on Monday that it will cease its partnership with Hims & Hers Health (NYSE:HIMS), ending the direct access to Wegovy, its weight loss drug, through NovoCare Pharmacy. In ...

Patients who redeemed the $199 Wegovy savings offer between May 22 and June 30 are eligible for the $299 price on one fill between July 1 and July 31. For subsequent months, self-paying patients ...

Novo Nordisk said on Thursday it would offer temporary discounts to cash-paying customers for its weight-loss drug Wegovy, in a move that coincides with a deadline for halting sales of cheaper ...

Global Wegovy sales reached 17.36 billion Danish kroner during the first quarter of 2025, coming in 7% below analyst expectations, according to a note from analysts with ODDO BHF.

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down. The Danish company is citing a steep decline in the company’s share price.